ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication
Main Category: BipolarArticle Date: 13 Mar 2005 - 12:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate article
Tokyo (JCNN) - Bristrol-Myers Squibb (BMS) and Otsuka Pharmaceutical have jointly announced that the US Food and Drug Administration (FDA) approved an additional indication for ABILIFY (aripiprazole) Tablets and Oral Solution, atypical antipsychotics, as of March 1.
With this approval, ABILIFY is now applicable to the maintenance treatment, namely preventing relapses, of bipolar I disorder. Since its initial approval in 2002, over 3.7 million prescriptions have been written in the US.
In Japan, ABILIFY , for which a new drug application was filed in March 2003, is currently under examination.
View Otsuka Pharmaceutical Co., Ltd. company profile here
Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.
View drug information on Abilify.
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Bipolar headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
